TaiGen Biopharmaceuticals Holdings (ROCO:4157) ROE %: 83.24% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4157 TaiGen Biopharmaceuticals Holdings Ltd ROCO:4157
59 GF Score
Price NT$8.87
GF Value NT$34.16
Valuation Significantly Undervalued
View Full Analysis

What is TaiGen Biopharmaceuticals Holdings ROE %?

TaiGen Biopharmaceuticals Holdings ROCO:4157 +3.14% 59 ROE % is 83.24% as of Dec. 2025. GuruFocus rates ROCO:4157 with a GF Score™ of 59/100 and a GF Value™ of NT$34.16 (Significantly Undervalued). Among 1,249 Biotechnology companies, TaiGen Biopharmaceuticals Holdings ranks better than 82.95% on this metric.

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. TaiGen Biopharmaceuticals Holdings's annualized net income for the quarter that ended in Dec. 2025 was NT$818.9 Mil. TaiGen Biopharmaceuticals Holdings's average Total Stockholders Equity over the quarter that ended in Dec. 2025 was NT$983.8 Mil. Therefore, TaiGen Biopharmaceuticals Holdings's annualized ROE % for the quarter that ended in Dec. 2025 was 83.24%.

The historical rank and industry rank for TaiGen Biopharmaceuticals Holdings's ROE % or its related term are showing as below:

ROCO:4157' s ROE % Range Over the Past 10 Years
Min: -64.39   Med: -12.42   Max: 91.47
Current: 4.46

During the past 13 years, TaiGen Biopharmaceuticals Holdings's highest ROE % was 91.47%. The lowest was -64.39%. And the median was -12.42%.

ROCO:4157's ROE % is ranked better than
82.95% of 1249 companies
in the Biotechnology industry
Industry Median: -38.45 vs ROCO:4157: 4.46

TaiGen Biopharmaceuticals Holdings  (ROCO:4157) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2025 )
=Net Income/Total Stockholders Equity
=818.876/983.778
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(818.876 / 924.864)*(924.864 / 1090.318)*(1090.318 / 983.778)
=Net Margin %*Asset Turnover*Equity Multiplier
=88.54 %*0.8483*1.1083
=ROA %*Equity Multiplier
=75.11 %*1.1083
=83.24 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2025 )
=Net Income/Total Stockholders Equity
=818.876/983.778
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (818.876 / 867.42) * (867.42 / 750.736) * (750.736 / 924.864) * (924.864 / 1090.318) * (1090.318 / 983.778)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.944 * 1.1554 * 81.17 % * 0.8483 * 1.1083
=83.24 %

Note: The net income data used here is four times the quarterly (Dec. 2025) net income data. The Revenue data used here is four times the quarterly (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


TaiGen Biopharmaceuticals Holdings ROE % Related Terms


TaiGen Biopharmaceuticals Holdings ROE % Historical Data

* Premium members only.

The historical data trend for TaiGen Biopharmaceuticals Holdings's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TaiGen Biopharmaceuticals Holdings ROE % Chart

TaiGen Biopharmaceuticals Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 91.47 -21.33 13.09 -3.51 4.19

TaiGen Biopharmaceuticals Holdings Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.98 -8.52 -48.71 -6.00 83.24

ROCO:4157 vs VRTX, REGN, ALNY: ROE % Comparison

For the Biotechnology subindustry, TaiGen Biopharmaceuticals Holdings's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TaiGen Biopharmaceuticals Holdings ROE % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TaiGen Biopharmaceuticals Holdings's ROE % distribution charts can be found below:

* The bar in red indicates where TaiGen Biopharmaceuticals Holdings's ROE % falls into.


ROCO:4157
59GF Score
TaiGen Biopharmaceuticals Holdings Ltd ROCO:4157
ROE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TaiGen Biopharmaceuticals Holdings ROE % Calculation

TaiGen Biopharmaceuticals Holdings's annualized ROE % for the fiscal year that ended in Dec. 2025 is calculated as

ROE %=Net Income (A: Dec. 2025 )/( (Total Stockholders Equity (A: Dec. 2024 )+Total Stockholders Equity (A: Dec. 2025 ))/ count )
=45.178/( (1082.326+1074.877)/ 2 )
=45.178/1078.6015
=4.19 %

TaiGen Biopharmaceuticals Holdings's annualized ROE % for the quarter that ended in Dec. 2025 is calculated as

ROE %=Net Income (Q: Dec. 2025 )/( (Total Stockholders Equity (Q: Sep. 2025 )+Total Stockholders Equity (Q: Dec. 2025 ))/ count )
=818.876/( (892.679+1074.877)/ 2 )
=818.876/983.778
=83.24 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2025) net income data. ROE % is displayed in the 30-year financial page.

Frequently Asked Questions Learn more about ROE % →
What does a ROE % of 83.24% mean?
TaiGen Biopharmaceuticals Holdings (ROCO:4157) has a ROE % of 83.24% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on TaiGen Biopharmaceuticals Holdings and its competitors. According to the industry distribution chart, TaiGen Biopharmaceuticals Holdings ranks #213 out of 1249 companies in the Biotechnology industry, placing it in the top 17.1%.
Is TaiGen Biopharmaceuticals Holdings' ROE % too high?
TaiGen Biopharmaceuticals Holdings' current ROE % is 83.24%. Based on the distribution chart, TaiGen Biopharmaceuticals Holdings ranks #213 out of 1249 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, TaiGen Biopharmaceuticals Holdings has a GF Score™ of 59/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TaiGen Biopharmaceuticals Holdings' ROE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, TaiGen Biopharmaceuticals Holdings ranks #213 out of 1249 companies for ROE %. This places TaiGen Biopharmaceuticals Holdings in the top 17% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Biotechnology company?
A good ROE % depends on the Biotechnology industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on TaiGen Biopharmaceuticals Holdings and its competitors. TaiGen Biopharmaceuticals Holdings's current ROE % is 83.24%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TaiGen Biopharmaceuticals Holdings stock overvalued right now?
Based on GuruFocus' analysis, TaiGen Biopharmaceuticals Holdings (ROCO:4157) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$34.16, compared to a current price of NT$8.87 — trading 74% below its estimated fair value. The current ROE % is 83.24%. TaiGen Biopharmaceuticals Holdings' overall GF Score™ is 59/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For TaiGen Biopharmaceuticals Holdings (ROCO:4157), the current ROE % is 83.24% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TaiGen Biopharmaceuticals Holdings (ROCO:4157) Overvalued in 2026?

Based on GuruFocus' analysis, TaiGen Biopharmaceuticals Holdings stock appears to be undervalued. The current stock price of NT$8.87 is trading 74% below its estimated GF Value™ of NT$34.16. GuruFocus considers TaiGen Biopharmaceuticals Holdings to be Significantly Undervalued.

Key valuation signals for ROCO:4157:

  • ROE %: 83.24%
  • GF Value™: NT$34.16 vs. price of NT$8.87 (74% below fair value)
  • GF Score™: 59/100

No single metric tells the full story. See the ROCO:4157 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


TaiGen Biopharmaceuticals Holdings Business Description

Address No. 138 Xinming Road, 7th Floor, Neihu District, Taipei, TWN, 114
TaiGen Biopharmaceuticals Holdings Ltd is mainly engaged in the research and development of new drugs, including the selection of drug candidates, pre-IND trials and clinical trials. Its operating segment includes development, research and sales of new drugs, and other. The majority of the revenue is generated from development, research and sales of new drugs.
59GF Score

Get the complete analysis for ROCO:4157

ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$8.87
Price
NT$34.16
GF Value